Essentia Health Menu
Home > Education & Research > Research to Improve Health Care > Participating in Research > Clinical Trials > Clinical Trials Details
Back to Results
The purpose of the study is to show that sotagliflozin can decrease the risk of cardiovascular death, or decreases the risk of being hospitalized for heart failure.
SOLOIST is a Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of SOtagLiflozin on Clinical Outcomes in HemodynamIcally STable Patients with Type 2 Diabetes POST Worsening Heart Failure.
Essentia Health East
For more information about a financial conflict of interest (FCOI), review the Essentia Health FCOI policy.
Last Updated: 05/29/2019